Logo

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE-TN Trial for Patients with Previously Untreated Chronic Lymphocytic Leukemia

Share this

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE-TN Trial for Patients with Previously Untreated Chronic Lymphocytic Leukemia

Shots:

  • The P-III ELEVATE-TN trial involves assessing of Calquence (100 mg bid) as monothx and + obinutuzumab vs chlorambucil + obinutuzumab in 535 patients in ratio (1:1:1) with previously untreated CLL
  • The study resulted in meeting 1EPs & 2EPs with improvement in PFS as monothx & combination and was safe & well-tolerated when compared with the CT-based combination of chlorambucil and obinutuzumab
  • Calquence is a Bruton tyrosine kinase (BTK) inhibitor has received the US FDA’s accelerated approval in Oct 2017 for patients with 1L MCL in adults and is currently evaluated in multiple P-III trials in CLL including ASCEND- ELEVATE-TN- ELEVATE-RR (ACE-CL-006)

Ref: AstraZeneca | Image: AstraZeneca

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions